Curative
A healthcare services company, Curative offers an employer-based health plan with no co-pays, deductibles, or coinsurance for qualifying members.
Secondary Market Price
How Curative Measures Up
To help you manage your Curative equity, Prospect has run the company through our machine learning model.
Prospect Rating
--
This rating reflects our belief in this company's potential to grow to that many times its current value in 4 years. For an employee with stock, this rating suggests a potential return on equity, but it also comes with some risk.
Exit Risk
--
Our rating is a reflection of the likelihood of this company achieving a liquidity event for its employees based on the quality of investors, funding stage, founders, and more.
Funding Stage
Series B
A company’s funding stage reflects how established it is, how quickly it is scaling, and the average impact an employee may have when joining.
Secondary Market Price Chart
Create a free account to unlock real-time secondary market prices and future projections of Curative's value.
Sign up to Unlock the Latest DataData will be available soon.
Sign up to receive notifications when it is available.
Prospect Projected Future Curative Prices
Prospect’s machine learning model has been trained on the same data top-tier investors use to project the likely range of outcomes for Curative's equity. Create a free account to view 10th-90th percentile projections over 2, 4, and 6 years.
Powerful tools to earn more from your equity
Company Description
Curative is a healthcare services company that provides an employer-based health insurance plan. The company's model focuses on preventive care, offering members $0 co-pays, deductibles, and coinsurance if they complete an annual "Baseline Visit." While Curative serves employers headquartered in Texas, Florida, and Georgia, its members have nationwide network access. Founded in 2020 by Fred Turner and Isaac Turner, the company initially operated as a large-scale COVID-19 testing provider before pivoting to the health insurance industry.
The company plans to expand its health insurance offerings to employers in additional states. Curative recently raised $150 million in a Series B funding round, which brought its valuation to $1.275 billion. The company has reported that within a year of a group joining its plan, there is a 20% increase in primary care engagement, a 30% reduction in hospitalizations, and up to a 40% reduction in drug costs. Curative is also leveraging AI to reduce administrative friction in healthcare workflows for providers and members.
- Upside Vision Fund
- Justin Mateen
- Mike Novogratz
- Stanley Druckenmiller's Duquesne Family Office
- DCVC
- Martin Varsavsky
- Co-Founder, Fred Turner
- Co-Founder, Isaac Turner
- Co-Founder, Vlad Slepnev
Peer Group Comparison
Vs Peer Group of >$4B Startups
Frequently Asked Questions
Joining Anduril as an employee is another way to acquire equity, typically through stock options included in compensation packages.
Is Curative worth joining?
Deciding whether to join a company like Curative depends on your personal career goals and risk tolerance for startup equity. Tools like Prospect can help you make an informed decision by providing machine learning-driven projections on the potential value of your equity compensation.
What should I do with my Curative stock?
Managing your Curative stock involves complex decisions around when to exercise options and when to sell shares to maximize your earnings and minimize taxes. Platforms like Prospect can build a personalized, multi-year strategy based on your financial situation and the company's projected performance.
Can you sell Curative stock?
As a private company, Curative stock isn't traded on a public exchange, but employees can often sell shares through tender offers or on secondary markets. Prospect offers tools to help you determine how much to sell and which shares are the most tax-optimal to part with.
How can I find the value of my Curative stock?
Valuing stock in a private company like Curative is challenging because it doesn't have a public market price. You can use a platform like Prospect, which uses machine learning models and data from secondary markets to project your equity's potential future value.
What is Curative's equity worth?
The precise worth of private equity like Curative's is not public information and can fluctuate based on company performance and market conditions. Services like Prospect can help you understand the potential range of outcomes by providing data-driven projections for your holdings.
What is Curative's stock ticker symbol?
Curative is a private company, so it does not have a stock ticker symbol. Ticker symbols are used to identify companies that are traded on public stock exchanges.
Can I buy or sell Curative stock?
As an employee, you can "buy" Curative stock by exercising your stock options, and you may be able to sell shares during company-approved tender offers or on secondary markets. Tools from Prospect can help you create tax-optimized strategies for both exercising and selling your shares.
What is the criteria to buy or invest in Curative stock?
Investing in a private company like Curative is generally limited to employees who receive equity as part of their compensation or to accredited investors during specific funding rounds. Platforms such as Prospect are designed to help employees manage the equity they already own, rather than facilitate new investments.
